Health Care & Life Sciences » Biotechnology | Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
84.45 M
Public Float
52.34 M
Progenics Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.9
Market Cap
$496.59 M
Shares Outstanding
84.74 M
Public Float
83.85 M

Profile

Address
One World Trade Center
New York New York 1000
United States
Employees -
Website http://www.progenics.com
Updated 07/08/2019
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J.

Financials

View All

Mark Robert Baker
Chief Executive Officer & Director
Peter J. Crowley
Chairman